# Plain RAG on Spastic paraplegia 93, autosomal recessive (NFU1, OMIM:620938)
model: gemini-3.8-flash   generated: 2026-09-28 20:49

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `NFU1 gene Spastic paraplegia 93, autosomal recessive`

[1] **620938 - SPASTIC PARAPLEGIA 93, AUTOSOMAL ...**  
    https://omim.org/entry/620938  
    Autosomal recessive spastic paraplegia-93 (SPG93) is characterized by a spectrum of early-onset pure to complex hereditary spastic paraplegia phenotypes ...

[2] **Spastic Paraplegia 93, Autosomal Recessive (SPG93)**  
    https://www.malacards.org/card/spastic_paraplegia_93_autosomal_recessive  
    Autosomal recessive spastic paraplegia 93 (SPG93) is caused by homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13.

[3] **hereditary spastic paraplegia 93 - ZFIN Human Disease**  
    https://zfin.org/DOID:0070645  
    Human Gene, Zebrafish Ortholog, OMIM Term, Disease, OMIM Phenotype ID. NFU1 · nfu1. Spastic paraplegia 93, autosomal recessive, hereditary spastic paraplegia 93 ...

[4] **Gene: NFU1 (Childhood onset hereditary spastic paraplegia)**  
    https://panelapp.genomicsengland.co.uk/panels/568/gene/NFU1/  
    Mode of inheritance. BIALLELIC, autosomal or pseudoautosomal ; Phenotypes Spastic paraplegia 93, autosomal recessive, OMIM:620938; spastic ...

[5] **hereditary spastic paraplegia 93**  
    https://www.alliancegenome.org/disease/DOID:0070645  
    A hereditary spastic paraplegia that has_material_basis_in homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13.

[6] **hereditary spastic paraplegia 93 | SGD**  
    https://www.yeastgenome.org/disease/DOID:0070645  
    A hereditary spastic paraplegia that has_material_basis_in homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13. Synonyms: autosomal ...

## 2. The context handed to the model
```
[1] 620938 - SPASTIC PARAPLEGIA 93, AUTOSOMAL ...
https://omim.org/entry/620938
Autosomal recessive spastic paraplegia-93 (SPG93) is characterized by a spectrum of early-onset pure to complex hereditary spastic paraplegia phenotypes ...

[2] Spastic Paraplegia 93, Autosomal Recessive (SPG93)
https://www.malacards.org/card/spastic_paraplegia_93_autosomal_recessive
Autosomal recessive spastic paraplegia 93 (SPG93) is caused by homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13.

[3] hereditary spastic paraplegia 93 - ZFIN Human Disease
https://zfin.org/DOID:0070645
Human Gene, Zebrafish Ortholog, OMIM Term, Disease, OMIM Phenotype ID. NFU1 · nfu1. Spastic paraplegia 93, autosomal recessive, hereditary spastic paraplegia 93 ...

[4] Gene: NFU1 (Childhood onset hereditary spastic paraplegia)
https://panelapp.genomicsengland.co.uk/panels/568/gene/NFU1/
Mode of inheritance. BIALLELIC, autosomal or pseudoautosomal ; Phenotypes Spastic paraplegia 93, autosomal recessive, OMIM:620938; spastic ...

[5] hereditary spastic paraplegia 93
https://www.alliancegenome.org/disease/DOID:0070645
A hereditary spastic paraplegia that has_material_basis_in homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13.

[6] hereditary spastic paraplegia 93 | SGD
https://www.yeastgenome.org/disease/DOID:0070645
A hereditary spastic paraplegia that has_material_basis_in homozygous or compound heterozygous mutation in the NFU1 gene on chromosome 2p13. Synonyms: autosomal ...
```

## 3. The gene, from the sources

The human gene *NFU1* is located on chromosome 2p13 [2, 5]. Biallelic mutations in *NFU1*, occurring as homozygous or compound heterozygous variants, are the material basis of autosomal recessive spastic paraplegia 93 (SPG93) [2, 4, 5, 6]. Under OMIM entry 620938, this condition is classified as a childhood-onset hereditary spastic paraplegia [1, 4]. Clinically, SPG93 is characterized by a phenotypic spectrum ranging from early-onset pure to complex hereditary spastic paraplegia [1]. In cross-species genetics, *nfu1* is recognized as the zebrafish ortholog of the human *NFU1* gene [3]. 

However, the provided sources do not cover what the specific *NFU1* gene product is [1, 2]. Furthermore, what the gene product does in the cell and the exact mechanisms detailing how variants in *NFU1* cause disease are not covered in the text [2, 5].

*tokens in 595, out 1808*

## 4. The gene, closed book (no sources; beware hallucinations)

).
                  Phenotype: Spastic paraplegia 93, autosomal recessive, 620630, AR.
                  Who published the report that led to SPG93?
                  Let's recall the citation details:
                  Journal: Could it be *Journal of Medical Genetics*, *Neurogenetics*, *Brain*, or *Clinical Genetics*?
                  Let's think:
                  Wait, could it be:
                  "Minardi et al. (2023)"?
                  Wait, let's recall:
                  Could it be:
                  "Loss of NFU1 causes a mild mitochondrial phenotype manifesting as spastic paraplegia..."
                  Wait, could it be:
                  "Mor

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P01)

Based on the provided sources, here is the clinical genetic assessment:

---

### 1. Patient Rule-In / Rule-Out Assessment

The provided sources define Spastic Paraplegia 93, Autosomal Recessive (SPG93) as being characterized by a "spectrum of early-onset pure to complex hereditary spastic paraplegia phenotypes" [1] (also described as "childhood onset hereditary spastic paraplegia" [4]) caused by homozygous or compound heterozygous mutations in the *NFU1* gene on chromosome 2p13 [2, 4, 5, 6]. 

The sources **do not** provide granular HPO term lists, detailed clinical exclusion criteria, or individual patient genotypes. Therefore, strictly using the provided sources, **no patient can be definitively ruled in**, as none have genetic confirmation of biallelic *NFU1* mutations [2, 4, 5, 6].

* **P01**: **Cannot be ruled in or ruled out.** The patient presents with *Spastic paraplegia*, *Spastic gait*, *Ataxia*, and limb weakness, which aligns with the "spectrum of early-onset pure to complex hereditary spastic paraplegia phenotypes" [1]. However, without *NFU1* sequencing data, they cannot be ruled in [2, 4].
* **P02**: **Cannot be ruled in; clinically inconsistent.** The patient presents primarily with congenital ocular, optic nerve, brain malformations, and profound delay without mention of spastic paraplegia [1]. While the sources do not provide explicit exclusion lists, this phenotype does not fit the cardinal description of spastic paraplegia [1].
* **P03**: **Cannot be ruled in; clinically inconsistent.** The presentation is an early infantile epileptic encephalopathy; although *Spasticity* is noted, there is no spastic paraplegia phenotype described [1].
* **P04**: **Cannot be ruled in or ruled out.** Features include *Spastic paraplegia*, Babinski sign, and impaired vibration sensation, matching a complex hereditary spastic paraplegia phenotype [1]. Definitively ruling in is impossible because the sources do not provide genetic data for this patient [2, 4].
* **P05**: **Cannot be ruled in or ruled out.** Features include *Paraplegia*, *Lower limb spasticity*, ataxia, and systemic features, which could represent a complex spastic paraplegia spectrum [1]. However, the sources provide no data on whether seizures or dysmorphic features belong to SPG93 [1], nor do they provide genetic confirmation [2].
* **P06**: **Cannot be ruled in or ruled out.** The patient has *Paraplegia*, hypertonia, and delayed walking, which could fall within early-onset spastic paraplegia [1, 4], but lack of genetic verification leaves this unconfirmed [2, 4].
* **P07**: **Cannot be ruled in or ruled out.** Presents with *Spasticity*, sensory loss, and ataxia (a complex HSP picture) [1], but no genetic confirmation for *NFU1* is provided [2, 5].
* **P08**: **Cannot be ruled in; clinically inconsistent.** The presentation is that of a severe lower motor neuron/axonal neuropathy and hypotonia with microcephaly, lacking spastic paraplegia [1]. 
* **P09**: **Cannot be ruled in or ruled out.** Presents with *Spastic paraplegia* and intellectual disability/deterioration, fitting a complex hereditary spastic paraplegia phenotype [1]. Definitive rule-in is not possible without *NFU1* genetic status [2, 4].
* **P10**: **Cannot be ruled in or ruled out.** Presents with *Lower limb spasticity*, ataxia, and hyperreflexia, consistent with complex spastic paraplegia [1], but lacks genetic proof [2, 4].

---

### 2. Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P01** (or alternatively **P04**)
  * *Reasoning:* P01 explicitly exhibits the core diagnostic term **Spastic paraplegia** [1, 4] alongside spastic gait, ataxia, impaired vibration sensation, and limb weakness, cleanly matching the definition of a "spectrum of early-onset pure to complex hereditary spastic paraplegia" [1]. 
* **Probability:** **~25%–30%**
  * *Reasoning:* Because the sources state only that SPG93 is an early-onset pure-to-complex spastic paraplegia [1, 4] and do not detail the specific distinguishing HPO manifestations or patient-specific genetic findings, there are multiple plausible candidates presenting with spastic paraplegia/spasticity (P01, P04, P05, P06, P07, P09, P10). Distributing likelihood strictly across these clinically compatible candidates gives an estimated probability of around 25%–30% for any single candidate, as the sources provide no quantitative or specific clinical details to elevate one with higher certainty.

---

### 3. Facts Needed to Be Confident (Not Provided in the Sources)

To establish a definitive diagnosis, the following information is required:
1. **Molecular Genetic Data:** Confirmation of homozygous or compound heterozygous pathogenic variants in the *NFU1* gene on chromosome 2p13 [2, 4, 5, 6].
2. **Age of Onset:** Specific verification of early/childhood onset for the spastic paraplegia phenotype in the patient [1, 4].
3. **Specific Clinical/HPO Delineation:** A granular description of the full clinical spectrum of SPG93 (e.g., frequency of peripheral neuropathy, ataxia, seizures, or cognitive regression), which is summarized only broadly in the provided text as "pure to complex" [1].
4. **Exclusion of Other Genetic Etiologies:** Targeted or exome sequencing data ruling out other hereditary spastic paraplegia (SPG) subtypes or neuromuscular disorders.

--------------------------------------------------------------------------------

### Round 2  (picked: P01)

Based on the provided sources, here is the clinical evaluation:

### 1. Patient Rule-In / Rule-Out Assessment

The provided sources define Spastic Paraplegia 93, Autosomal Recessive (SPG93) only as being caused by biallelic (homozygous or compound heterozygous) mutations in the *NFU1* gene [2, 4, 5, 6] and presenting as a spectrum of early-onset / childhood-onset pure to complex hereditary spastic paraplegia phenotypes [1, 4]. The sources provide no specific inclusion/exclusion HPO terms, detailed clinical descriptions, or negative diagnostic criteria. 

* **P01:** **Cannot rule in or rule out.** The presence of spastic paraplegia is compatible with the broad spectrum of hereditary spastic paraplegia phenotypes [1], but the sources do not provide detailed phenotypic criteria or genetic data to confirm or exclude this patient [1, 2].
* **P02:** **Cannot rule in or rule out.** The patient demonstrates upper motor neuron signs (Babinski sign, brisk reflexes), but the sources do not specify whether this constellation of complex neurological features fits SPG93, nor do they give genetic data [1, 2].
* **P03:** **Cannot rule in or rule out.** Demonstrates spasticity and neurodevelopmental abnormalities, which could conceivably fit a complex phenotype [1], but the sources lack the phenotypic detail or genetic testing results needed to confirm or exclude [1, 2].
* **P04:** **Cannot rule in or rule out.** Presents with spastic paraplegia and lower limb weakness, compatible with hereditary spastic paraplegia [1], but cannot be confirmed or excluded without genetic data or specific diagnostic criteria in the sources [1, 2].
* **P05:** **Cannot rule in or rule out.** Presents with paraplegia and lower limb spasticity alongside complex multisystem features, which cannot be confirmed or ruled out because the sources only vaguely mention "pure to complex" phenotypes [1] without specifying clinical boundaries [1, 2].
* **P06:** **Cannot rule in or rule out.** Features paraplegia and hypertonia, but the sources do not provide sufficient clinical or genetic details to rule them in or out [1, 2].
* **P07:** **Cannot rule in or rule out.** Features spasticity and motor signs compatible with spastic paraplegia [1], but the sources lack distinguishing clinical criteria or molecular data [1, 2].
* **P08:** **Cannot rule in or rule out.** While the phenotype is predominantly hypotonic and neuropathic rather than clearly spastic, the sources do not provide negative diagnostic criteria to definitively exclude this patient, nor genetic data to rule them in [1, 2].
* **P09:** **Cannot rule in or rule out.** Features spastic paraplegia with intellectual disability, which is broadly compatible with complex hereditary spastic paraplegia [1], but the sources provide no genetic data or specific criteria to confirm or exclude [1, 2].
* **P10:** **Cannot rule in or rule out.** Features lower limb spasticity and ataxia, which could fall within the pure-to-complex spectrum [1], but the sources provide no means to confirm or rule out the diagnosis [1, 2].

---

### 2. Most Likely Patient and Probability

* **Most Likely Patient:** **P01** (or alternatively **P04** or **P09**). 
  * *Reasoning:* P01, P04, and P09 are the only patients who explicitly exhibit the exact term "Spastic paraplegia," which matches the disease definition of SPG93 [1, 2, 3, 4, 5, 6]. Among these, P01 exhibits a classic presentation combining spastic paraplegia, spastic gait, and weakness [1].
* **Estimated Probability:** **~33%** (if restricted to the three patients explicitly presenting with spastic paraplegia; or **10%** if assuming a uniform prior across all 10 candidates, as the sources provide no clinical discriminators to favor one over the others).

---

### 3. Missing Information Needed for Diagnostic Confidence

To establish a definitive diagnosis, the following information is required that the provided sources do not contain:
1. **Molecular Genetic Data:** Confirmation of homozygous or compound heterozygous pathogenic variants in the *NFU1* gene on chromosome 2p13 [2, 4, 5, 6].
2. **Specific Clinical/HPO Phenotype Profiles:** Detailed clinical characterization or HPO profiles delineating what defines "pure to complex" SPG93 beyond the generic OMIM entry summary [1].
3. **Age of Onset:** Specific age of onset for each patient to assess whether it matches the documented "early-onset" [1] or "childhood onset" [4] criteria.
4. **Exclusionary Criteria:** Specific clinical findings that would definitively rule out SPG93 in complex neurological presentations.

--------------------------------------------------------------------------------

### Round 3  (picked: P05)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Patient Rule-In / Rule-Out Assessment

The sources state only that autosomal recessive spastic paraplegia-93 (SPG93) is characterized by "a spectrum of early-onset pure to complex hereditary spastic paraplegia phenotypes" [1] and is caused by biallelic (homozygous or compound heterozygous) mutations in the *NFU1* gene on chromosome 2p13 [2, 4, 5, 6]. Because the sources provide no detailed HPO terms, negative diagnostic criteria, or genetic testing results for these individuals [1–6], **no patient can be definitively ruled in or ruled out solely using the provided text.**

* **P01:** **Cannot be ruled in or ruled out.** The presence of "Spastic paraplegia" and "Spastic gait" is consistent with a spastic paraplegia phenotype [1], but the sources provide no genetic data or specific phenotype lists to confirm or exclude this patient [1–6].
* **P02:** **Cannot be ruled in or ruled out.** P02 has brisk reflexes and Babinski sign but lacks explicit spastic paraplegia [1]. However, the sources do not provide exclusion criteria or genetic data to definitively rule P02 out [1–6].
* **P03:** **Cannot be ruled in or ruled out.** P03 has spasticity, but the sources do not indicate whether epileptic encephalopathy and seizures fall within the SPG93 spectrum, nor are genetic data provided [1–6].
* **P04:** **Cannot be ruled in or ruled out.** The patient has "Spastic paraplegia" and lower limb weakness, fitting a spastic paraplegia phenotype [1], but the sources provide no electrophysiological criteria or *NFU1* sequencing data [1–6].
* **P05:** **Cannot be ruled in or ruled out.** The combination of motor delay, "Paraplegia", and "Lower limb spasticity" with multisystem features fits an early-onset complex hereditary spastic paraplegia phenotype [1], but the sources do not mention specific systemic features (e.g., lactic acidosis, seizures) or genetic confirmation [1–6].
* **P06:** **Cannot be ruled in or ruled out.** The presence of early walking delay, "Paraplegia", and hypertonia is compatible with early-onset complex spastic paraplegia [1], but brain MRI findings and genetic status are not detailed in the sources [1–6].
* **P07:** **Cannot be ruled in or ruled out.** Lower limb hyperreflexia and spasticity are compatible with spastic paraplegia features [1], but there is no genetic or detailed clinical information to confirm or exclude the diagnosis [1–6].
* **P08:** **Cannot be ruled in or ruled out.** P08 presents with hypotonia, hyporeflexia, and axonal neuropathy without spastic paraplegia [1]; while this makes SPG93 clinically improbable based on the name [1], the sources do not provide explicit exclusion criteria or genetic testing to formally rule P08 out [1–6].
* **P09:** **Cannot be ruled in or ruled out.** P09 presents with mild global developmental delay and "Spastic paraplegia", which aligns with an early-onset complex spastic paraplegia phenotype [1], but genetic and detailed clinical confirmation is absent [1–6].
* **P10:** **Cannot be ruled in or ruled out.** Lower limb spasticity and hyperreflexia can be seen in spastic paraplegia [1], but no genetic or definitive phenotypic data are available to confirm or exclude P10 [1–6].

---

### 2. Single Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P05** 
  * *Reasoning:* Source [1] specifies that SPG93 encompasses "early-onset pure to complex hereditary spastic paraplegia phenotypes." P05 demonstrates clear early-onset disease (motor delay, global developmental delay) combined with a complex presentation involving paraplegia, lower limb spasticity, ataxia, and cerebral atrophy [1]. (Patients P01, P04, P06, and P09 also manifest paraplegia or spastic paraplegia [1]).
* **Estimated Probability:** **~20%**
  * *Reasoning:* The provided sources do not supply distinguishing clinical details or genetic data [1–6]. Because at least five patients (P01, P04, P05, P06, P09) present with phenotypes compatible with "pure to complex hereditary spastic paraplegia" [1], the probability of any single candidate from the text alone cannot be stated with certainty and is roughly an equal split among compatible candidates (~1 in 5, or ~20%).

---

### 3. Facts Needed to Be Confident (Not in the Sources)

1. **Molecular Genetic Testing:** Confirmation of homozygous or compound heterozygous (biallelic) pathogenic variants in the *NFU1* gene on chromosome 2p13 in the patient [2, 4, 5, 6].
2. **Specific Clinical / HPO Phenotype Profiles:** Detailed inclusion and exclusion criteria or an enumeration of associated features (e.g., whether lactic acidosis, seizures, neuropathy, or specific brain anomalies occur in SPG93), which are entirely omitted from the sources [1–6].
3. **Inheritance and Family History:** Confirmation of autosomal recessive inheritance in the patient's pedigree [1, 2, 4].

--------------------------------------------------------------------------------

picks across rounds: ['P01', 'P01', 'P05']
